Cooper Companies Stock: Is COO Underperforming the Healthcare Sector?
Cooper Companies (COO) develops contact lenses and surgical products through CooperVision and CooperSurgical. The stock is 24.6% below its 52-week high ($89.83) and has underperformed XLV over 3 months (+2.1% for XLV vs. -3.1% for COO) and 52 weeks (-2.8% vs. +12.3%). After Q2 2026 results on June 5, shares rose 8.6% as revenue reached $1.1B (+7.9%) and adjusted EPS was $1.21. Analysts (17) rate it “Moderate Buy” with a mean target of $81.60.
How this was made
The 30-second read
Why it matters
The text highlights a Q2 2026 earnings beat (revenue and adjusted EPS) and a June 5 stock jump, while also emphasizing relative underperformance versus XLV and current moving-average positioning.
Market read
Traders get a recap of COO’s Q2 2026 earnings beat and the immediate post-earnings move, plus relative performance vs XLV and basic technical context.
What to watch
The article cites technical positioning (below 200-day, above 50-day) but provides no guidance details, margin commentary, or forward demand indicators that would confirm sustained re-rating.
Background
COO is described as operating in CooperVision and CooperSurgical, with contact lens products across spherical/toric/multifocal categories.
Ticker impact
Article notes COO rose 8.6% on June 5 after Q2 2026 earnings, with revenue up 7.9% to $1.1B and adjusted EPS $1.21 beating estimates.
Bias modestly positive for near-term trading, but follow-through risk remains given the article’s focus on lagging vs XLV and moving-average positioning.
The only concrete fundamental datapoints are the Q2 2026 results (revenue/EPS) and the June 5 reaction; the rest is comparative performance and technical levels without new disclosures.
Market effects
Limited read-across: the article is single-name performance/earnings recap for a medical devices supplier, not a sector-wide regulatory/product shift.
No explicit regional macro or policy drivers; primarily US-listed stock performance.
No global supply-chain, competition, or regulatory developments disclosed.
Counterpoint
COO’s longer-term underperformance vs XLV (down 2.8% vs XLV up 12.3% over 52 weeks) suggests the earnings beat may not have changed the broader relative trend.
Key entities
- companyThe Cooper Companies, Inc.
Subject of the article; Q2 2026 earnings beat and subsequent stock reaction are cited.
- ETFState Street Healthcare Select Sector SPDR ETF
Used as a benchmark for relative performance (XLV up vs COO down over 3 and 52 weeks).
- companySolventum Corporation
Mentioned as a rival for relative performance comparison (no separate news disclosed).
